InvestLog
KRRO Korro Bio, Inc. logo

KRRO Korro Bio, Inc.

Healthcare
$11.61+3.66%ClosedMarket Cap: $115.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.13

P/S

30.08

EV/EBITDA

-1.24

DCF Value

$-0.53

FCF Yield

-61.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

73.2%

Operating Margin

-2154.0%

Net Margin

-2954.1%

ROE

-117.9%

ROA

-61.8%

ROIC

-48.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-19.6M$—
Q4 null$1.3M$-50.0M$—
FY null$6.4M$-117.3M$—
Q3 null$1.1M$-18.1M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$19.57

Target (Median)

$22.00

Target Range

$10.00 - $30.00

2 Strong Buy7 Buy2 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-05-19
Raymond JamesOutperform
2026-03-13
Cantor FitzgeraldOverweight
2026-03-13
Clear StreetBuy
2026-02-19
William BlairOutperform
2026-02-17

Trading Activity

Insider Trades

View All
Lynx1 Capital Management LP10 percent owner
BuyThu Apr 02
Lynx1 Capital Management LP10 percent owner
SellThu Apr 02
Yang Rick10 percent owner
BuyThu Mar 12
Yang Rick10 percent owner
BuyThu Mar 12
SANDELL SCOTT D10 percent owner
BuyThu Mar 12

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

2.23

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Peers

ALT logoALTAMRN logoAMRNANNX logoANNXANRO logoANROAURA logoAURADBVT logoDBVTENGN logoENGNLBRX logoLBRXLRMR logoLRMRSLN logoSLN